Myasthenia Gravis (MG) is a neuromuscular disorder characterized by rapid fatigue and muscle weakness. It primarily affects voluntary muscles, with generalized myasthenia gravis impacting multiple muscle groups throughout the body. Juvenile myasthenia gravis is a rare autoimmune disorder affecting the neuromuscular junction (NMJ) and typically manifests before the age of 18 years.

Myasthenia Gravis (MG) is characterized by a variety of symptoms, most commonly including: 

- Facial Changes: Alterations in facial expressions, difficulty smiling, and a mask-like facial appearance.

- Limb Weakness: Weakness in the arms and legs can lead to abnormal gait.

- Ptosis: Drooping of one or both eyelids.

 - Speech Impairment: Difficulty speaking due to weakened speech muscles.

- Generalized Weakness: Weakness in the legs, arms, and neck.

- Diplopia (Double Vision): Double vision, either vertical or horizontal, which may improve when one or both eyes are closed.

- Swallowing and Chewing Difficulties: Problems with swallowing and chewing food.

- Respiratory and Motor Control Issues: Difficulty breathing, controlling head movements, and using the arms for tasks.

These symptoms can vary in severity and may fluctuate over time, often worsening with activity and improving with rest.

Myasthenia gravis is caused by a problem with the signals sent between the nerves and the muscles.

It's an autoimmune condition, which means it's the result of the immune system (the body's natural defense against infection) mistakenly attacking a healthy part of the body.

In myasthenia gravis, the immune system damages the communication system between the nerves and muscles, making the muscles weak and easily tired.

It's not clear why this happens, but it's been linked to issues with the thymus gland (a gland in the chest that's part of the immune system).

Many people with myasthenia gravis have a thymus gland that's larger than normal. Around 1 in 10 people have an abnormal growth of the thymus called a thymoma.

·       Women under 40 and men over 60: are more likely to develop MG. Women between the ages of 20–30 and men between the ages of 60–70 are at particular risk. 

·       Genetic markers: People with certain human leukocyte antigen (HLA) genotypes, such as HLA-B8 and HLA-DR3, are more likely to develop MG. 

·       Family history

·       Newborns whose mothers have MG may develop a temporary condition called neonatal MG. This occurs when the mother's abnormal antibodies enter the baby's bloodstream. 

·       Other factors

These include: 

• Infections, such as Epstein-Barr virus (EBV) and cytomegalovirus (CMV) 

• Exposure to certain medications, such as antibiotics and beta-blockers 

• Hormonal factors, including fluctuations in estrogen levels 

• Thymic abnormalities, such as thymomas and thymic hyperplasia 

• Physical inactivity 

• Insufficient diet 

• Stress 

• Thymectomy (surgery to remove the thymus) 

• Type 2 diabetes, especially in women older than 50.

1.Medications:

Cyclosporine

Cholinesterase inhibitors (e.g., Mestinon)

Corticosteroids (e.g., Rayos)

Immunosuppressants (e.g., mycophenolate mofetil, azathioprine, methotrexate, tacrolimus)

2. Surgery

Robot-assisted thymectomy

Video-assisted thymectomy

3.Intravenous Therapy:

Plasmapheresis

Monoclonal antibodies (e.g., Rituximab, eculizumab)

Intravenous immunoglobulin (IVIG)

Stem cell therapy (SCT) offers a promising alternative for treating myasthenia gravis, particularly for patients resistant to other treatments. Mesenchymal stem cells (MSCs) possess immunomodulatory and anti-inflammatory properties, providing a long-term, improved prognosis by addressing the underlying cause rather than just symptoms. MSC transplantation can be especially beneficial for patients with cellular structure disturbances.

Neurological diseases like stroke, Parkinson's disease, and Alzheimer's disease have high mortality and morbidity rates, impairing brain function. Traditional treatments include endovascular thrombectomy (ET), intravenous tissue plasminogen activator (IV-tPA), and medications.

A modern approach involves using exosomes with stem cell therapy. Research indicates that exosomes enhance:

- Angiogenesis

- Neurogenesis in ischemic boundary zones

- Neurite remodeling

- Synaptic plasticity

Combining stem cell therapy with exosomes can improve functional recovery, tissue repair, and cellular regeneration in individuals with neurological disorders.

Post-Stroke Benefits of Exosomal Therapy:

 Oligodendrogenesis: Formation of new oligodendrocytes

Remyelination: Restoration of the myelin sheath

Axonal Sprouting: Growth of new axons

Exosomes also boost the expression of neuroprotective microRNAs (miR-133b, miR-210, miR-184, miR-17-92), aiding in disease prognosis.

These advanced treatments offer comprehensive solutions for managing myasthenia gravis and associated neurological disorders, providing hope for improved patient outcomes and quality of life.

At Renue we believe that if you are truly interested in Healthspan (Living better, not just longer.”) then it’s important that we are aware of our Biological Age vs Chronological Age.  Remember you can”t measure success without a starting point.  With TruDiagnostic’s TruAge testy you will receive 9 personalized Epigenetic Health Scores and actionable insights to slow aging

Biological Age

How old your body is compared to your real age

Pace of Aging

How quickly you're aging each year

Organ System Ages

The age of key organs (heart, brain, liver, etc.)

Fitness Age

Your physical health based on strength, lung capacity, and movement

Smoking Impact

How smoking has affected your epigenetic age

Alcohol Impact

How alcohol consumption has influenced your health